These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 22971289

  • 1. Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer.
    Switzer CH, Cheng RY, Ridnour LA, Glynn SA, Ambs S, Wink DA.
    Breast Cancer Res; 2012 Sep 12; 14(5):R125. PubMed ID: 22971289
    [Abstract] [Full Text] [Related]

  • 2. S-nitrosylation of Ras in breast cancer.
    Marshall HE, Foster MW.
    Breast Cancer Res; 2012 Nov 12; 14(6):113. PubMed ID: 23167903
    [Abstract] [Full Text] [Related]

  • 3. Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer.
    Basudhar D, Glynn SA, Greer M, Somasundaram V, No JH, Scheiblin DA, Garrido P, Heinz WF, Ryan AE, Weiss JM, Cheng RYS, Ridnour LA, Lockett SJ, McVicar DW, Ambs S, Wink DA.
    Proc Natl Acad Sci U S A; 2017 Dec 05; 114(49):13030-13035. PubMed ID: 29087320
    [Abstract] [Full Text] [Related]

  • 4. Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients.
    Glynn SA, Boersma BJ, Dorsey TH, Yi M, Yfantis HG, Ridnour LA, Martin DN, Switzer CH, Hudson RS, Wink DA, Lee DH, Stephens RM, Ambs S.
    J Clin Invest; 2010 Nov 05; 120(11):3843-54. PubMed ID: 20978357
    [Abstract] [Full Text] [Related]

  • 5. Candidate pathways linking inducible nitric oxide synthase to a basal-like transcription pattern and tumor progression in human breast cancer.
    Ambs S, Glynn SA.
    Cell Cycle; 2011 Feb 15; 10(4):619-24. PubMed ID: 21293193
    [Abstract] [Full Text] [Related]

  • 6. S-nitrosylation of EGFR and Src activates an oncogenic signaling network in human basal-like breast cancer.
    Switzer CH, Glynn SA, Cheng RY, Ridnour LA, Green JE, Ambs S, Wink DA.
    Mol Cancer Res; 2012 Sep 15; 10(9):1203-15. PubMed ID: 22878588
    [Abstract] [Full Text] [Related]

  • 7. Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression.
    Heinecke JL, Ridnour LA, Cheng RY, Switzer CH, Lizardo MM, Khanna C, Glynn SA, Hussain SP, Young HA, Ambs S, Wink DA.
    Proc Natl Acad Sci U S A; 2014 Apr 29; 111(17):6323-8. PubMed ID: 24733928
    [Abstract] [Full Text] [Related]

  • 8. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
    Phelps M, Darley M, Primrose JN, Blaydes JP.
    Cancer Res; 2003 May 15; 63(10):2616-23. PubMed ID: 12750288
    [Abstract] [Full Text] [Related]

  • 9. Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer.
    Switzer CH, Glynn SA, Ridnour LA, Cheng RY, Vitek MP, Ambs S, Wink DA.
    Trends Pharmacol Sci; 2011 Nov 15; 32(11):644-51. PubMed ID: 21893353
    [Abstract] [Full Text] [Related]

  • 10. Nitric oxide-targeted therapy inhibits stemness and increases the efficacy of tamoxifen in estrogen receptor-positive breast cancer cells.
    López-Sánchez LM, Mena R, Guil-Luna S, Mantrana A, Peñarando J, Toledano-Fonseca M, Conde F, De la Haba-Rodríguez JR, Aranda E, Rodríguez-Ariza A.
    Lab Invest; 2021 Mar 15; 101(3):292-303. PubMed ID: 33262438
    [Abstract] [Full Text] [Related]

  • 11. Nitric Oxide Synthase-2-Derived Nitric Oxide Drives Multiple Pathways of Breast Cancer Progression.
    Basudhar D, Somasundaram V, de Oliveira GA, Kesarwala A, Heinecke JL, Cheng RY, Glynn SA, Ambs S, Wink DA, Ridnour LA.
    Antioxid Redox Signal; 2017 Jun 20; 26(18):1044-1058. PubMed ID: 27464521
    [Abstract] [Full Text] [Related]

  • 12. LINE-1 ORF-1p functions as a novel HGF/ETS-1 signaling pathway co-activator and promotes the growth of MDA-MB-231 cell.
    Yang Q, Feng F, Zhang F, Wang C, Lu Y, Gao X, Zhu Y, Yang Y.
    Cell Signal; 2013 Dec 20; 25(12):2652-60. PubMed ID: 24012497
    [Abstract] [Full Text] [Related]

  • 13. Assessing the predictive response of a simple and sensitive blood-based biomarker between estrogen-negative solid tumors.
    Mohan S, Patel S, Barlow D, Rojas AC.
    Adv Med Sci; 2020 Sep 20; 65(2):424-428. PubMed ID: 32919119
    [Abstract] [Full Text] [Related]

  • 14. Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer.
    Naderi A, Meyer M.
    Breast Cancer Res; 2012 Jul 20; 14(4):R111. PubMed ID: 22817771
    [Abstract] [Full Text] [Related]

  • 15. NOS2 and COX-2 Co-Expression Promotes Cancer Progression: A Potential Target for Developing Agents to Prevent or Treat Highly Aggressive Breast Cancer.
    Coutinho LL, Femino EL, Gonzalez AL, Moffat RL, Heinz WF, Cheng RYS, Lockett SJ, Rangel MC, Ridnour LA, Wink DA.
    Int J Mol Sci; 2024 Jun 01; 25(11):. PubMed ID: 38892290
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Assessing N w-hydroxy-L-arginine applicability as a novel ethnic specific estrogen-negative breast cancer marker.
    Mohan S, Greenstein I, Ng C, Frazier K, Nguyen G, Harding L, Barlow D.
    Amino Acids; 2018 Apr 01; 50(3-4):373-382. PubMed ID: 29260322
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.